Watch and wait

OTHER5 trials

Conditions

Colorectal Cancer Stage IIColorectal Cancer Stage IIILocally Advanced Rectal CancerMantle Cell LymphomaMild Autonomous Cortisol Secretion (MACS)Rectal Cancer

Phase 2

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Active, not recruitingNCT04304209

Sun Yat-sen UniversityColorectal Cancer Stage II, Colorectal Cancer Stage III

Start: 2019-10-28End: 2026-10-18Target: 195Updated: 2023-02-01

Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

RecruitingNCT06204094

Jinhua Central HospitalLocally Advanced Rectal Cancer

Start: 2024-02-05End: 2028-09-01Target: 37Updated: 2025-01-07

Phase 3

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

CompletedNCT00921414

French Innovative Leukemia OrganisationMantle Cell Lymphoma

Start: 2008-09-30End: 2017-02-28Updated: 2018-04-27

Phase 4

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

RecruitingNCT07268222

Laikο General Hospital, AthensMild Autonomous Cortisol Secretion (MACS)

Start: 2025-12-01End: 2027-11-25Target: 150Updated: 2025-12-05

Unknown Phase

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

RecruitingNCT04643041

Sixth Affiliated Hospital, Sun Yat-sen UniversityRectal Cancer

Start: 2021-01-01End: 2026-12-31Target: 47Updated: 2025-12-12

Blood2024-11-05

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Blood2024-11-05

Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.

2024-08-0149 citations

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood2024-04-2610 citations

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood2023-11-029 citations

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Blood2023-11-023 citations

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood2023-11-02

Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.

Journal of Clinical Oncology2023-06-011 citations

Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.

2023-03-0199 citations

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.

2022-02-113 citations

Neoadjuvant chemoradiotherapy with or without Pd-1 antibody sintilimab for pMMR/MSS/MSI-L locally advanced rectal cancer: A randomized controlled study (cohort B).

Journal of Clinical Oncology2022-01-191 citations

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

Cancers2021-09-078 citations

Pd1 antibody sintilimab for dMMR/MSI-H locally advanced rectal cancer: An open-label, phase 2, single-arm study (cohort A).

Journal of Clinical Oncology2021-05-209 citations

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Blood2020-11-049 citations

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Blood2020-11-04

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

New England Journal of Medicine2017-09-27398 citations

Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the <scp>LyMA</scp> trial conducted on behalf the <scp>LYSA</scp> group

Hematological Oncology2017-06-012 citations

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

Blood2016-12-0243 citations

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Blood2015-12-0322 citations

Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group

Blood2015-12-037 citations

1 more papers not shown